An-Najah's BioSciences Unit Signs an MOU with Sama Pharmaceuticals Manufacturing Company
On Wednesday, May 8, 2019, An-Najah's BioSciences Unit (NBU) and Sama Pharmaceuticals Manufacturing Company signed a clinical study agreement.
An-Najah was represented by Professor Maher Natsheh, Acting President, and Dr. Amjad Hussain, Director of An-Najah's BioSciences Unit (NBU) whereas Sama Pharmaceuticals Manufacturing Company was represented by Eng. Mahmoud Al-Zalmout, Chairman, and Dr. Adeeb Saifi, General Manager.
Under this agreement, An-Najah's BioSciences Unit (NBU) will compare a drug produced and manufactured by Sama with an original, brand version of the drug after getting the approval from the Ministry of Health.
It is worth mentioning that An-Najah's BioSciences Unit (NBU) has received the Palestinian Ministry of Health accreditation and license, making An-Najah National University the first university in Palestine to establish a center for conducting bioequivalence studies following international standards.
The newly established Center is not only the first of its kind to be accredited in Palestine, but only among ten bioequivalence specialized centers in the Arab world, and it will undoubtedly contribute to a quantum leap in the pharmaceutical industry and will offer a unique service to Palestinian citizens.
The Center will be devoted to providing Bioequivalence (BE) studies on locally produced drugs and medicinal products in compliance with national and international guidelines and with therapeutic equivalence evaluations.